Q3 Earnings Estimate for PTCT Issued By William Blair

Key Points

• William Blair forecasts PTC Therapeutics to report a Q3 2025 earnings per share of ($1.51), while the consensus estimate for the full year is ($4.52) per share.
• Multiple analysts have recently adjusted their price targets for PTC Therapeutics, with Wells Fargo raising it to $78.00 and Royal Bank of Canada to $58.00, reflecting positive outlooks.
• PTC Therapeutics reported $10.04 earnings per share last quarter, significantly exceeding expectations of $0.85, alongside a revenue of $1.18 billion.

PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) - Research analysts at William Blair issued their Q3 2025 earnings estimates for PTC Therapeutics in a report released on Tuesday, July 29th. William Blair analyst S. Corwin anticipates that the biopharmaceutical company will post earnings of ($1.51) per share for the quarter. The consensus estimate for PTC Therapeutics' current full-year earnings is ($4.52) per share. William Blair also issued estimates for PTC Therapeutics' Q4 2025 earnings at ($1.25) EPS, Q1 2026 earnings at ($0.70) EPS, Q2 2026 earnings at ($0.60) EPS, Q3 2026 earnings at ($0.48) EPS, Q4 2026 earnings at ($0.23) EPS and FY2026 earnings at ($2.01) EPS.

PTC Therapeutics (NASDAQ:PTCT - Get Free Report) last issued its earnings results on Tuesday, May 6th. The biopharmaceutical company reported $10.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.85 by $9.19. The firm had revenue of $1.18 billion for the quarter, compared to the consensus estimate of $437.16 million. PTC Therapeutics had a net margin of 33.56% and a negative return on equity of 78.56%. The business's revenue was down 9.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($1.20) earnings per share.

Other research analysts also recently issued reports about the company. Barclays upped their price target on PTC Therapeutics from $42.00 to $46.00 and gave the company an "equal weight" rating in a report on Tuesday, July 29th. Citigroup restated a "neutral" rating and set a $50.00 target price (up previously from $40.00) on shares of PTC Therapeutics in a research note on Monday, July 28th. Robert W. Baird reduced their price target on shares of PTC Therapeutics from $70.00 to $66.00 and set an "outperform" rating for the company in a research note on Wednesday, May 7th. Wells Fargo & Company boosted their price objective on shares of PTC Therapeutics from $74.00 to $78.00 and gave the company an "overweight" rating in a report on Tuesday, July 29th. Finally, UBS Group raised their target price on shares of PTC Therapeutics from $71.00 to $80.00 and gave the stock a "buy" rating in a report on Tuesday, July 29th. One analyst has rated the stock with a sell rating, four have given a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $69.38.

PTC Therapeutics Trading Up 0.7%

PTCT traded up $0.37 during trading on Thursday, hitting $52.50. 259,471 shares of the company's stock traded hands, compared to its average volume of 1,049,087. The stock has a market capitalization of $4.16 billion, a price-to-earnings ratio of 8.07 and a beta of 0.54. The company's 50 day simple moving average is $49.21 and its two-hundred day simple moving average is $48.79. PTC Therapeutics has a 12-month low of $29.01 and a 12-month high of $58.38.

Insider Transactions at PTC Therapeutics

In other PTC Therapeutics news, VP Mark Elliott Boulding sold 883 shares of the firm's stock in a transaction that occurred on Friday, May 16th. The shares were sold at an average price of $46.02, for a total transaction of $40,635.66. Following the sale, the vice president owned 103,901 shares in the company, valued at approximately $4,781,524.02. This trade represents a 0.84% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Pierre Gravier sold 2,516 shares of the firm's stock in a transaction on Tuesday, July 15th. The shares were sold at an average price of $49.46, for a total transaction of $124,441.36. Following the sale, the chief financial officer owned 71,920 shares in the company, valued at $3,557,163.20. The trade was a 3.38% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 5,328 shares of company stock valued at $254,158. Company insiders own 5.50% of the company's stock.

Institutional Trading of PTC Therapeutics

Several institutional investors have recently made changes to their positions in PTCT. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in PTC Therapeutics by 0.3% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 65,681 shares of the biopharmaceutical company's stock worth $2,967,000 after purchasing an additional 205 shares in the last quarter. Summit Investment Advisors Inc. lifted its position in shares of PTC Therapeutics by 3.3% in the fourth quarter. Summit Investment Advisors Inc. now owns 7,968 shares of the biopharmaceutical company's stock worth $360,000 after buying an additional 253 shares in the last quarter. Xponance Inc. boosted its stake in PTC Therapeutics by 5.2% during the first quarter. Xponance Inc. now owns 6,372 shares of the biopharmaceutical company's stock valued at $325,000 after buying an additional 314 shares during the last quarter. PNC Financial Services Group Inc. boosted its stake in PTC Therapeutics by 84.2% during the first quarter. PNC Financial Services Group Inc. now owns 700 shares of the biopharmaceutical company's stock valued at $36,000 after buying an additional 320 shares during the last quarter. Finally, Diversified Trust Co increased its stake in PTC Therapeutics by 2.0% in the 1st quarter. Diversified Trust Co now owns 17,147 shares of the biopharmaceutical company's stock worth $874,000 after acquiring an additional 329 shares during the last quarter.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.